De Volder J, Bontinck A, Haelterman V, Boon L, Joos G, Brusselle G
Respir Res. 2025; 26(1):43.
PMID: 39875874
PMC: 11773929.
DOI: 10.1186/s12931-024-03082-9.
Buchanan D, Mori S, Chadli A, Panda S
Biomedicines. 2025; 13(1).
PMID: 39857823
PMC: 11763372.
DOI: 10.3390/biomedicines13010240.
Li Z, Yan X, Wei J, Pu L, Zhu G, Cao Y
Front Pharmacol. 2023; 14:1224906.
PMID: 37456754
PMC: 10340118.
DOI: 10.3389/fphar.2023.1224906.
Al-Kuraishy H, Hussien N, Al-Niemi M, Fahad E, Al-Buhadily A, Al-Gareeb A
Immun Inflamm Dis. 2023; 11(5):e861.
PMID: 37249296
PMC: 10187021.
DOI: 10.1002/iid3.861.
Wang T, Zhai Y, Xue H, Zhou W, Ding Y, Nie H
Biomolecules. 2023; 13(4).
PMID: 37189326
PMC: 10135759.
DOI: 10.3390/biom13040578.
Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport.
Fu Y, Xue H, Wang T, Ding Y, Cui Y, Nie H
Biomed Pharmacother. 2023; 163:114863.
PMID: 37172333
PMC: 10169260.
DOI: 10.1016/j.biopha.2023.114863.
Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA.
Pisareva E, Mihalovicova L, Pastor B, Kudriavtsev A, Mirandola A, Mazard T
Genome Med. 2022; 14(1):135.
PMID: 36443816
PMC: 9702877.
DOI: 10.1186/s13073-022-01125-8.
Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection.
Akbasheva O, Spirina L, Dyakov D, Masunova N
Biochem Mosc Suppl B Biomed Chem. 2022; 16(4):271-291.
PMID: 36407837
PMC: 9668222.
DOI: 10.1134/S1990750822040035.
Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute phase COVID-19 patients.
Pisareva E, Badiou S, Mihalovicova L, Mirandola A, Pastor B, Kudriavtsev A
J Med Virol. 2022; 95(1):e28209.
PMID: 36226380
PMC: 9874393.
DOI: 10.1002/jmv.28209.
Competitive cleavage of SARS-CoV-2 spike protein and epithelial sodium channel by plasmin as a potential mechanism for COVID-19 infection.
Hou Y, Yu T, Wang T, Ding Y, Cui Y, Nie H
Am J Physiol Lung Cell Mol Physiol. 2022; 323(5):L569-L577.
PMID: 36193902
PMC: 9639761.
DOI: 10.1152/ajplung.00152.2022.
Host/genetic factors associated with COVID-19 call for precision medicine.
Thierry A
Precis Clin Med. 2022; 3(3):228-234.
PMID: 35960669
PMC: 7454858.
DOI: 10.1093/pcmedi/pbaa026.
On the Origin of Neutrophil Extracellular Traps in COVID-19.
Pastorek M, Dubrava M, Celec P
Front Immunol. 2022; 13:821007.
PMID: 35359960
PMC: 8961727.
DOI: 10.3389/fimmu.2022.821007.
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.
Yamada S, Asakura H
Int J Mol Sci. 2022; 23(6).
PMID: 35328761
PMC: 8955234.
DOI: 10.3390/ijms23063338.
NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.
Zhu Y, Chen X, Liu X
Front Immunol. 2022; 13:838011.
PMID: 35309344
PMC: 8924116.
DOI: 10.3389/fimmu.2022.838011.
Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza.
Cambier S, Metzemaekers M, de Carvalho A, Nooyens A, Jacobs C, Vanderbeke L
JCI Insight. 2021; 7(1).
PMID: 34793331
PMC: 8765057.
DOI: 10.1172/jci.insight.155055.
Neutrophil extracellular traps (NETs): the role of inflammation and coagulation in COVID-19.
Jing H, Chen X, Zhang S, Liu H, Zhang C, Du J
Am J Transl Res. 2021; 13(8):8575-8588.
PMID: 34539980
PMC: 8430084.
Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza.
Rahbar Saadat Y, Hosseiniyan Khatibi S, Zununi Vahed S, Ardalan M
Front Mol Biosci. 2021; 8:725528.
PMID: 34527703
PMC: 8435734.
DOI: 10.3389/fmolb.2021.725528.
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.
Ji H, Wagener B, Ness T, Zhao R
Pulm Pharmacol Ther. 2021; 70:102055.
PMID: 34271164
PMC: 8276553.
DOI: 10.1016/j.pupt.2021.102055.
Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19.
Sharma C, Jha N, Meeran M, Patil C, Goyal S, Ojha S
Front Pharmacol. 2021; 12:603997.
PMID: 34248612
PMC: 8265778.
DOI: 10.3389/fphar.2021.603997.
Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets.
Hazeldine J, Lord J
Front Immunol. 2021; 12:680134.
PMID: 34149717
PMC: 8206563.
DOI: 10.3389/fimmu.2021.680134.
